Find in Library

The identification of novel prognostic biomarkers for breast cancer is an unmet clinical need. Cullin-associated and neddylation-dissociated 1 (CAND1) has been implicated in mediating carcinogenesis in prostate and lung cancers. In addition, CAND1 is an established prognostic biomarker for worse prognosis in liver cancer. However, the prognostic significance of <i>CAND1</i> in breast cancer has not yet been explored. In this study, Breast Cancer Gene-Expression Miner (Bc-GenExMiner) and TIMER2.0 were utilized to explore the mRNA expression of <i>CAND1</i> in ERα-positive breast cancer patients. The Kaplan–Meier plotter was used to explore the relationship between <i>CAND1</i> expression and several prognostic indicators. The Gene Set Cancer Analysis (GSCA) web server was then used to explore the pathways of the genes that correlate with <i>CAND1</i> in ERα-positive breast cancer. Immune infiltration was investigated using Bc-GenExMiner. Our bioinformatics analysis illustrates that breast cancer patients have higher <i>CAND1</i> compared to normal breast tissue and that ERα-positive breast cancer patients with a high expression of <i>CAND1</i> have poor overall survival (OS), distant metastasis-free survival (DMFS), and relapse-free survival (RFS) outcomes. Higher <i>CAND1</i> expression was observed in histologic grade 3 compared to grades 2 and 1. Our results revealed that <i>CAND1</i> positively correlates with lymph nodes and negatively correlates with the infiltration of immune cells, which is in agreement with published reports. Our findings suggest that <i>CAND1</i> might mediate invasion and metastasis in ERα-positive breast cancer, possibly through the activation of estrogen and androgen signaling pathways; however, experiments should be carried out to further explore the role of <i>CAND1</i> in activating the androgen and estrogen signaling pathways. In conclusion, the results suggest that <i>CAND1</i> could be used as a potential novel biomarker for worse prognosis in ERα-positive breast cancer.